Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health MS Step Therapy Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 3431-D

    Medicare Part B Step Therapy Multiple Sclerosis

    Customize your policy alerts

    Sign up for zing_health Policy 3431-D alerts

    Get alerted when Policy 3431-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for preferred and non-preferred multiple sclerosis products administered under Medicare Part B. It applies to members requesting a non-preferred product and provides clinical exception criteria based on prior treatment, inadequate response, adverse events, or contraindications.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Multiple Sclerosis
    Policy CodePolicy 3431-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for non-preferred products through the clinical exception process.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred products
    4Non-preferred products
    365 daysPrior-use lookback
    Medicare Part BBenefit
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred products required or excluded

    Applicable Coverage Criteria

    Applicable Indication

    Coverage applies when the requested treatment is for an FDA-approved indication for the preferred product.

    The requested treatment is for an FDA-approved indication for the preferred product.

    Initial Therapy: Lemtrada or Briumvi

    Coverage for Lemtrada or Briumvi is provided when ANY of the following criteria are met:

    ANY of the following

    • Member has received treatment with the non-preferred product in the past 365 days.Within the past 365 days
    • Member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with both of the preferred products or any of their components.

    Initial Therapy: Ocrevus Zunovo

    Coverage for Ocrevus Zunovo is provided when ANY of the following criteria are met:

    ANY of the following

    • Member has received treatment with the non-preferred product in the past 365 days.Within the past 365 days
    • ALL of the following

      • Member has had a documented intolerable adverse event with the preferred product, Ocrevus, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
      • Member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with the preferred product, Tysabri, or any of its components.

    Initial Therapy: Tyruko

    Coverage for Tyruko is provided when ANY of the following criteria are met:

    ANY of the following

    • Member has received treatment with the non-preferred product in the past 365 days.Within the past 365 days
    • ALL of the following

      • Member has had a documented intolerable adverse event with the preferred product, Tysabri, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).
      • Member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with the preferred product, Ocrevus, or any of its components.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for non-preferred products through the clinical exception process. Preferred products may also require a clinical prior authorization review, and step therapy applies in addition to any applicable NCD, LCD, or Medicare Part B utilization management program.

    • Applies to all members requesting treatment with a non-preferred multiple sclerosis product.
    • The program applies when the requested indication is FDA-approved for the applicable preferred product.
    Step Therapy

    Document Preferred-Product Step Therapy

    Before requesting a non-preferred product, document whether the corresponding preferred products have been tried, are clinically inappropriate, or are otherwise excluded. Preferred products are Ocrevus (ocrelizumab) and Tysabri (natalizumab); their use or exclusion is evaluated by requested product.

    • Lemtrada or Briumvi: address both preferred products, Ocrevus and Tysabri, or any of their components.

    Policy Background

    This policy manages Medicare Part B coverage for multiple sclerosis products. Ocrevus and Tysabri are preferred products; Briumvi, Lemtrada, Ocrevus Zunovo, and Tyruko are non-preferred products subject to prior authorization through the clinical exception process. Exceptions may be based on prior product use or clinical circumstances that exclude use of the preferred products. Preferred products may also require clinical prior authorization review, and step therapy applies in addition to applicable Medicare coverage and utilization-management programs.

    Key Terms

    Step therapy
    DefinitionA coverage management process requiring use of preferred products before coverage of a non-preferred product.
    Preferred-product requirementPreferred products must be used before coverage of a non-preferred product is considered.
    ExceptionsCoverage of a non-preferred product may be available when clinical circumstances exclude use of the preferred product.
    Clinical exception
    DefinitionA situation in which clinical circumstances exclude use of the preferred product.
    Prior treatmentA clinical exception may be based on prior use of a product.

    Product-Specific Initial Therapy

    Lemtrada or Briumvi

    Coverage for Lemtrada or Briumvi is provided when either of the following criteria is met.

    Lemtrada or Briumvi exception

    • Recent prior use: The member has received treatment with the requested non-preferred product in the past 365 days.past 365 days
    • Preferred-product failure or contraindication: The member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with both preferred products or any of their components.

    Ocrevus Zunovo

    Coverage for Ocrevus Zunovo is provided when either of the following criteria is met.

    Ocrevus Zunovo exception

    Preferred and Non-Preferred Products

    StepPreferred product(s)Non-preferred product(s)Requirements for coverage
    1Ocrevus (ocrelizumab); Tysabri (natalizumab)Lemtrada (alemtuzumab); Briumvi (ublituximab-xiiy)Either the member received the requested non-preferred product within the past 365 days, or the member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with both preferred products or any of their components.
    StepPreferred product(s)Non-preferred productRequirements for coverage
    2Ocrevus (ocrelizumab); Tysabri (natalizumab)Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)Either the member received Ocrevus Zunovo within the past 365 days, or both criteria are met: a documented intolerable adverse event with Ocrevus that was not an expected adverse event attributed to the active ingredient as described in the prescribing information, and a documented inadequate response, intolerable adverse event, or contraindication to therapy with Tysabri or any of its components.
    StepPreferred product(s)Non-preferred productRequirements for coverage
    2Ocrevus (ocrelizumab); Tysabri (natalizumab)Tyruko (natalizumab-sztn)Either the member received Tyruko within the past 365 days, or both criteria are met: a documented intolerable adverse event with Tysabri that was not an expected adverse event attributed to the active ingredient as described in the prescribing information, including a known adverse reaction for both reference and biosimilar products, and a documented inadequate response, intolerable adverse event, or contraindication to therapy with Ocrevus or any of its components.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Multiple Sclerosis
    Policy CodePolicy 3431-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for non-preferred products through the clinical exception process.
    SourceLink
    On This Page
    Applicable Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundKey TermsProduct-Specific Initial TherapyPreferred and Non-Preferred Products
  1. Ocrevus Zunovo: address Ocrevus and Tysabri, as specified in the exception criteria.
  2. Tyruko: address Tysabri and Ocrevus, as specified in the exception criteria.
  3. Documentation Required

    Clinical Exception Documentation

    Submit documentation supporting a qualifying clinical exception for the requested non-preferred product. Coverage is available when the member received the requested non-preferred product within the past 365 days, or when the product-specific exception criteria are documented.

    • Lemtrada or Briumvi: document inadequate response, an intolerable adverse event, or a contraindication to both Ocrevus and Tysabri, or any of their components.
    • Ocrevus Zunovo: document the required Ocrevus adverse event plus inadequate response, intolerable adverse event, or contraindication to Tysabri or any of its components.
    • Tyruko: document the required Tysabri adverse event plus inadequate response, intolerable adverse event, or contraindication to Ocrevus or any of its components.
    Documentation Required

    Document Intolerance or Adverse Events

    When relying on intolerance or an adverse event, document the clinically significant event involving the applicable preferred product and explain why it supports the exception. For Ocrevus Zunovo and Tyruko, the event must not be an expected adverse event attributed to the active ingredient as described in the prescribing information.

    • Ocrevus Zunovo: document an intolerable adverse event with Ocrevus that is not an expected active-ingredient adverse event, plus a qualifying failure, intolerance, or contraindication involving Tysabri.
    • Tyruko: document an intolerable adverse event with Tysabri that is not an expected active-ingredient adverse event, plus a qualifying failure, intolerance, or contraindication involving Ocrevus.
    • The Tyruko criterion applies to known adverse reactions for both reference and biosimilar products.
    Denial Risk

    Exception Criteria Not Met

    A non-preferred product may be denied when the requested treatment is not for an indication FDA-approved for the applicable preferred product, or when the product-specific clinical exception requirements are not met.

    • Lemtrada or Briumvi: denial risk applies if there is no treatment within the past 365 days and no documented inadequate response, intolerable adverse event, or contraindication to both preferred products or their components.
    • Ocrevus Zunovo: denial risk applies if there is no treatment within the past 365 days and both required exception elements are not documented.
    • Tyruko: denial risk applies if there is no treatment within the past 365 days and both required exception elements are not documented.
    Denial Risk

    No Qualifying Preferred-Product Exception

    Coverage is at denial risk when prior use of the requested non-preferred product within the past 365 days or a qualifying clinical exception is not documented. Submit records identifying the product, treatment history, response, adverse event, contraindication, and affected components as applicable.

    • Non-preferred products: Briumvi (ublituximab-xiiy), Lemtrada (alemtuzumab), Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), and Tyruko (natalizumab-sztn).
    • Documentation must support the applicable preferred-product trial or exclusion; an unsupported request may be denied.
    Other support
    Other documented clinical factors may support an exception to preferred-product use.
    • Recent prior use: The member has received treatment with Ocrevus Zunovo in the past 365 days.past 365 days
    • Required adverse event and preferred-product failure

      • Ocrevus adverse event: The member has had a documented intolerable adverse event with the preferred product, Ocrevus, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
      • Tysabri failure or contraindication: The member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with the preferred product, Tysabri, or any of its components.

    Tyruko

    Coverage for Tyruko is provided when either of the following criteria is met.

    Tyruko exception

    • Recent prior use: The member has received treatment with Tyruko in the past 365 days.past 365 days
    • Required adverse event and preferred-product failure

      • Tysabri adverse event: The member has had a documented intolerable adverse event with the preferred product, Tysabri, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information, including a known adverse reaction for both the reference product and biosimilar products.
      • Ocrevus failure or contraindication: The member has a documented inadequate response, intolerable adverse event, or contraindication to therapy with the preferred product, Ocrevus, or any of its components.